SAN FRANCISCO & SUZHOU, China, April 9, 2026
Innovent Biologics, Inc. has unveiled preclinical data for its novel tri-specific T-cell engager IBI3055 at the Immune Resetting: B-Cell Mediated & Beyond Summit 2026, highlighting a promising new approach for treating autoimmune diseases driven by B cells and plasma cells. The investigational therapy demonstrates potent immune cell depletion, targeted action, and favorable safety profiles, positioning it as a next-generation biologic candidate in the rapidly evolving field of immunotherapy.
Tri-Specific Antibody Targets Multiple Immune Pathways
IBI3055 is a proprietary tri-specific antibody engineered to simultaneously target CD19, BCMA, and CD3, enabling a multi-pronged immune modulation strategy. Built using an innovative “1+1+1” T-cell engager format, the molecule incorporates CD3 masking technology, which helps reduce non-specific T-cell activation while maintaining potent therapeutic activity. This design allows for target-dependent immune activation, improving both efficacy and safety balance, a critical challenge in autoimmune therapy development.
Preclinical studies demonstrated that IBI3055 effectively induces cytotoxic activity against both CD19- and BCMA-positive cells, regardless of expression levels. This capability ensures broader applicability across diverse autoimmune disease profiles, where immune cell heterogeneity often limits treatment effectiveness. The therapy’s ability to engage multiple immune pathways simultaneously represents a significant advancement in precision immunotherapy, offering a more comprehensive approach to disease control.
Strong Preclinical Results Show Deep Immune Cell Depletion
Advertisement
In transgenic mouse models and non-human primate studies, IBI3055 demonstrated deep and sustained depletion of B cells and plasma cells across multiple compartments, including peripheral blood, spleen, lymph nodes, and bone marrow. These effects were accompanied by a significant reduction in circulating immunoglobulin levels, indicating effective suppression of disease-driving immune activity.
Notably, the therapy exhibited greater activity compared to mono-targeting T-cell engagers, suggesting superior therapeutic potential. At the same time, the studies confirmed favorable safety and tolerability profiles, which are essential for advancing into clinical trials. These findings underscore the potential of IBI3055 to achieve durable immune resetting, a key goal in treating chronic autoimmune conditions where long-term disease control remains challenging.
Advancing Biopharma Innovation in Autoimmune Diseases
The development of IBI3055 reflects a broader shift in the biopharmaceutical industry toward multi-specific biologics and advanced immune engineering technologies. Autoimmune diseases represent a significant global burden, with many patients experiencing incomplete responses to existing therapies, highlighting the need for innovative treatment approaches.
Innovent’s strategy focuses on delivering therapies that combine high efficacy with improved safety profiles, addressing key limitations of current immunotherapies. The introduction of CD3 masking technology within the tri-specific format represents a notable innovation, helping to minimize off-target effects and immune-related toxicities, which are common concerns in T-cell engager therapies.
From a cGxP and regulatory perspective, the progression of IBI3055 from preclinical research toward clinical development will require strict adherence to GCP, GMP, and regulatory validation processes, particularly given the complexity of biologic manufacturing and multi-specific antibody design. The promising data presented at this international summit highlights the potential for IBI3055 to become a clinically transformative therapy, pending further validation in human trials.
The presentation of preclinical data for IBI3055 by Innovent Biologics marks a significant milestone in the development of next-generation autoimmune therapies, showcasing the potential of tri-specific T-cell engagers to deliver targeted and durable immune modulation. By combining innovative antibody engineering, strong preclinical efficacy, and improved safety design, this therapy represents a promising advancement in addressing unmet medical needs in autoimmune diseases. As the program advances toward clinical evaluation, it is expected to play a key role in shaping the future of precision immunotherapy and biologics innovation.
Source: Innovent Biologics press release
